ALGS - Aligos Therapeutics To Present Late Breaking Poster on ALG-000184 its CAM-E Drug Candidate at The Liver Meeting® 2023 | Benzinga
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that an abstract for its capsid assembly modulator – empty (CAM-E) drug candidate, ALG-000184, has been accepted as a late breaking poster at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD), in Boston, Massachusetts, November 10 – 14, 2023.
The poster (#5028-C), titled "Long-term dosing with the capsid assembly modulator ALG-000184 results in multi-log reductions of DNA, RNA, HBsAg, HBeAg, and HBcrAg in untreated HBeAg positive chronic hepatitis B subjects," will be presented in Poster Hall C on Monday, November 13 from 1-2 pm ET. The presenting author is Dr. Man-Fung (MF) Yuen, Chair and Professor of Gastroenterology and Hepatology at the University of Hong Kong.
About Aligos
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become ...